WuXi Biologics (HKEX: 2269) is a leading global Contract Development and Manufacturing Organization (CDMO) providing end-to-end biologics discovery, development, and manufacturing services — including monoclonal antibodies, bispecifics, antibody-drug conjugates, and recombinant proteins — from sites in China, Ireland, the U.S., and Singapore.
Company Info
Recent News
WuXi Biologics' MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy (PR Newswire FDA.)
After a 'redesign,' WuXi Biologics announces a new completion timeline for its Massachusetts manufacturing facility, amid ongoing US-China biopharma tensions.
Leadership Team
Chief Executive Officer
Careers & Job Openings